Rethinking Clinical Trials

JULY 9, 2023

However, persons in low-income and rural communities have significantly higher odds of receiving a prescription opioid for a new back pain diagnosis. Use of nonpharmacologic pain treatments is lower in rural settings and for persons of Hispanic/Latino ethnicity.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Research 130

Rethinking Clinical Trials

AUGUST 28, 2023

The American College of Physicians guideline states that “physicians and patients should treat acute, sub-acute and chronic LBP with non-drug therapies.” The study’s primary endpoints are a change in PROMIS physical function from baseline to 3 months and change in PROMIS pain interference from baseline to 3 months.

Trials 130

Trials Research Medicine Doctors 130

XTalks

DECEMBER 21, 2022

The multi-million-dollar price tags are largely attributable to the high R&D and manufacturing costs associated with making a gene therapy, as the raw materials for producing the therapy can be expensive. Currently, CSL Behring’s one-dose Hemophilia B gene therapy Hemgenix holds the title at $3.5 million for a single infusion.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52

The Pharma Data

MAY 4, 2021

Panzyga (immune globulin intravenous [human] ifas 10% liquid preparation) — In February 2021, Pfizer announced that the FDA approved the supplemental Biologics License Application (sBLA) for Panzyga to treat adult patients with a rare neurological disease of the peripheral nerves called chronic inflammatory demyelinating polyneuropathy (CIDP).

Vaccination 40

Vaccination Vaccine Production Sales 40